Study to Investigate DRP-104 in Adults With Advanced Solid Tumors

Stopped early · Phase 1/Phase 2

Conditions studied: Advanced Solid Tumor, Non Small Cell Lung Cancer Metastatic

In brief

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat) administered via intravenous infusion or via subcutaneous injection as a single agent and in combination with atezolizumab in patients with advanced solid tumors and to assess preliminary safety and efficacy of which route of administration (intravenous or subcutaneous) will be selected for further development for the one expansion of patients, advanced non-small cell lung cancer (NSCLC) with defined genetic mutations.

Key facts

Study ID

NCT04471415

Run by

Dracen Pharmaceuticals, Inc.

People needed

61

Starts

2020-08-31

Expected to finish

2023-03-28

Last updated by the study team

2023-06-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced or recurrent, histologically or cytologically confirmed, measurable by RECIST 1.1 metastatic or unresectable solid tumor
• Patient must have progressed on, be intolerant of, decline, or be ineligible for, all available standard of care therapies
• Part 2: locally advanced or metastatic NSCLC with KEAP1, NFE2L2 and/or STK11 mutation ; Patients must have received at least a platinum doublet chemotherapy and an anti-PD-(L)1 antibody; Received up to 3 lines of systemic anticancer therapy in the recurrent or metastatic setting
• Part 3 and 4 - DRP-104 + atezolizumab Prior exposure to any checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PDL2, and/or anti-CTLA-4 antibody)
• ECOG performance 0 or 1
• Patient must consent to allow acquisition of existing FFPE tumor tissue; If unavailable, patient must consent to new pre-treatment tumor biopsy
• All SCCHN patient, all NSCLC patients and all patients treated with combination of DRP-104 and atezolizumab will be required to undergo pre-treatment and post-treatment core or excisional biopsies.
• Pre-treatment and post-treatment core or excisional biopsies are optional for all remaining patients
• Adequate baseline organ function as defined by: Absolute neutrophil count ≥ 1.5 × 109/L (1500/µL); Hemoglobin ≥ 9 g/dL (patients that require transfusion or growth factors need to demonstrate stable hemoglobin of ≥ 9 g/dL over at least a 7-day period after the last transfusion/growth factor injection prior to screening labs to meet eligibility) ; Platelets ≥ 75 × 109/L (75,000/µL); Hepatic Total bilirubin ≤1.5 × upper limit of normal (ULN): PT/INR and PTT ≤1.5 × ULN, unless treated with warfarin; AST(SGOT)/ALT(SGPT) ≤3 × ULN or ≤ 5 × ULN for patients with liver metastases; Creatinine clearance ≥ 60 ml/min/1.73m2 measured or calculated
• Cardiac QTc (Fridericia) <470 ms
• Women of child-bearing potential and men who are sexually active must agree to use one highly effective method of contraception

You may not qualify if…

• Patients with primary central nervous system tumors and hepatocellular carcinoma
• Patients with progressive or symptomatic brain metastases or leptomeningeal disease
• Patients who have not recovered to grade 1 or baseline from adverse events (CTCAE v 5.0) related to prior therapy excluding alopecia, peripheral neuropathy and ototoxicity, which are excluded if ≥ grade 3.
• Lymphopenia ≤ grade 3 is allowed if not related to prior anticancer therapy. If related to prior anticancer therapy, lymphopenia must resolve to ≤ grade 1 or baseline.
• Spinal cord compression not definitively treated with surgery and/or radiation
• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage
• Prior glutaminase inhibitor use
• Prior systemic anticancer treatment (i.e., chemotherapy, biologic therapy, monoclonal antibodies, investigational agents) within 21 days or 5 half-lives, whichever is shorter
• Anti-androgen therapies for prostate cancer, such as bicalutamide, within 4 weeks prior to enrollment
• Patients must have recovered from all AEs due to previous therapies to CTCAE v 5.0 grade 1 or baseline, excluding, alopecia, peripheral neuropathy and ototoxicity, which must be at least grade 2 or baseline
• Prior small port palliative radiotherapy within 14 days of start of Cycle 1
• Any major surgery within 21 days from start of Cycle 1
• Secondary malignancy that is progressing or has required active treatment within the past 3 years, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy
• Has a known history of HIV or HBV
• Gastrointestinal (GI) function impairment or GI disease
• Significant, uncontrolled heart disease and/or cardiac repolarization abnormality
• Exclusion specific to only Part 3 and 4 (DRP-104 combined with atezolizumab):
• History of severe allergic, anaphylactic to chimeric or humanized antibodies or fusion proteins
• Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells
• Prior anti-PD-1, anti-PD-L1 and/or anti CTLA4- agent, patient must not have had a serious (> Grade 3) immune-related AE requiring treatment
• History of autoimmune disease except hypothyroidism on thyroid replacement hormone therapy, idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis
• Patients with underlying condition requiring systemic corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications or other systemic immunosuppressant medications may be enrolled in the study after approval by the Medical Monitor
• History of organ transplantation and/or hematopoietic stem cell transplantation
• Evidence or history of active or latent tuberculosis infection
• Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1

Where it is running

• HonorHealth — Scottsdale, Arizona, United States
• UCLA — Los Angeles, California, United States
• AdventHealth Medical Group — Kissimmee, Florida, United States
• Florida Cancer Specialist — Orlando, Florida, United States
• Johns Hopkins Kimmel Institute — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• NYU Langone — New York, New York, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• University of North Carolina — Chapel Hill, North Carolina, United States
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Sarah Cannon Research Institute — Nashville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• NEXT Oncology — Fairfax, Virginia, United States
• Centrum fur Integrieerte Onkologie — Cologne, Germany
• University Cancer Center NCT — Dresden, Germany
• University Hospital Frankfurt — Frankfurt, Germany
• University Klinikum Wuerzburg — Würzburg, Germany
• National Cancer Center Singapore — Singapore, Singapore
• Hospital University Vall d'Hebron — Barcelona, Spain
• University Hospital 12 de Octubre — Madrid, Spain
• National Taiwan University Hospital — Taipei, Taiwan
• Taipei Veterans General Hospital — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.